HJLI
NASDAQHancock Jaffe Laboratories, Inc.
Latest news
25 items- SECHancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- PRenVVeno Medical Corporation Successfully Completes RebrandingCompany Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc.For shareholders of the Company holding shares in electronic form, the name change will require no action. Shareholders with physical stock certificates should contact the Company's transfer agent to obtain new certificates.For more i
- PRHancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg ThalmannLive webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann on Monday, September 27, 2021 at 1:00 PM ET.The webinar will be moderated by Jeffrey S. Cohen, Managing Director of Ladenburg Thalmann. Following the discussion, there will be a question and answer se
- SECHancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- PRHancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which
- 13D/GSEC Form SC 13G filed by Hancock Jaffe Laboratories, Inc.SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)
- INSIDERSEC Form 4: Gray Robert converted options into 1,042 units of Common Stock, increasing direct ownership by 19% to 6,614 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- INSIDERSEC Form 4: Jenusaitis Matthew converted options into 1,042 units of Common Stock, increasing direct ownership by 22% to 5,884 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- PRHancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.As part of the call, management will discuss VenoValve's continued development and other ongoing corporate initiatives. The call will be led by Robert Berman, Chief Executive Officer of Hancock Jaffe, who will be joined by Dr. Marc Glickman
- SECSEC Form 8-K filed by Hancock Jaffe Laboratories, Inc.8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- SECSEC Form 424B5 filed by Hancock Jaffe Laboratories, Inc.424B5 - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- PRHancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ RulesIRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules.The offering consists of 2,540,650 shares of common stock and pre-funded warrants at a purchase price of $7.8720 per share. The gross proceeds are estimated to be $20 million before deducting the placement agent's fees and other estimated offer
- INSIDERSEC Form 4: Jenusaitis Matthew bought $10,010 worth of Common Stock (1,300 units at $7.70), increasing direct ownership by 37% to 4,842 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- PRHancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual MeetingTwo-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectivelyPatients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrencesNo safety issues occurred during the one-year reporting period following the study completionIRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, announced that promising two-year post-VenoValve® implantation data is being presented today at the Society for Vascular Surgery® (SVS) Annual Meeting in San Diego, CA by Dr. Jorg
- SECSEC Form 424B5 filed by Hancock Jaffe Laboratories, Inc.424B5 - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- SECSEC Form 8-K filed by Hancock Jaffe Laboratories, Inc.8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- SECSEC Form 424B3 filed by Hancock Jaffe Laboratories, Inc.424B3 - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- PRFDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions- Company preparing to begin SAVVE U.S. pivotal trial for VenoValve- VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their legsIRVINE, CA / ACCESSWIRE / August 3, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Design
- PRHancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare ConferenceLive webcast on Tuesday, July 13th at 1:00 PM ETIRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET.In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.A live webcast of Mr. Berman's presentation will be available on the Events page of the Inv
- INSIDERSEC Form 4: Gray Robert bought $12,500 worth of Common Stock (2,000 units at $6.25), increasing direct ownership by 56% to 5,572 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- SECSEC Form S-8 filed by Hancock Jaffe Laboratories, Inc.S-8 - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
- INSIDERSEC Form 4: Glickman Marc H. bought $9,440 worth of Common Stock (1,600 units at $5.90)4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- INSIDERSEC Form 4: BERMAN ROBERT ANDREW bought $16,410 worth of Common Stock (3,000 units at $5.47), increasing direct ownership by 408% to 3,736 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- INSIDERSEC Form 4: Duhay Francis bought $50,592 worth of Common Stock (9,492 units at $5.33), increasing direct ownership by 259% to 13,160 units4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- SECSEC Form 10-Q filed by Hancock Jaffe Laboratories, Inc.10-Q - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
HJLI FAQ
6 questionsWhat does Hancock Jaffe Laboratories, Inc. do?
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart...Where does HJLI stock trade?
Hancock Jaffe Laboratories, Inc. (HJLI) is listed on NASDAQ.What sector and industry is HJLI in?
Hancock Jaffe Laboratories, Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Hancock Jaffe Laboratories, Inc. go public?
Hancock Jaffe Laboratories, Inc. (HJLI) completed its IPO in 2018.What companies are similar to HJLI?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare HJLI side-by-side with any of them on Quantisnow.How can I track HJLI on Quantisnow?
Quantisnow aggregates Hancock Jaffe Laboratories, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HJLI to receive live email and push alerts on every new disclosure.